BioCryst Partners With Shionogi On Influenza Antiviral In Japan
This article was originally published in PharmAsia News
Executive Summary
BioCryst Pharmaceuticals and Shionogi & Company have signed an agreement giving the Japanese drug maker an exclusive license to develop and commercialize the Birmingham, Ala., company's Phase II influenza antiviral peramivir in Japan, the companies announced March 5